 RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the company will present three abstracts featuring new data on oral, once-daily ORLADEYO berotralstat for the prophylactic treatment of hereditary angioedema HAE at the 2022 American Academy of Allergy, Asthma Immunology AAAI annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022. 